Company intelligence
NRG ONCOLOGY
Advancing Research. Improving Lives.
Non-profit Organizations
PHILADELPHIA, US
57 employees
Founded 2014
8 public signals
About NRG ONCOLOGY
NRG Oncology is a non-profit research organization formed to conduct oncologic clinical research and to broadly disseminate study results for informing clinical decision making and healthcare policy.
Verified activity
Signals from NRG ONCOLOGY
8 published signals
Research & Knowledge
NRG ONCOLOGY published Protocol Activation NRG-GY038, a randomized Phase II trial comparing Sacituzumab Govitecan-Hziy (SG) and Bevacizumab with standard of care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in patients with platinum-sensitive ovarian cancer progressing on prior maintenance PARP inhibitor.
Reported by NRG ONCOLOGY
Legal & Regulatory
NRG ONCOLOGY closed all NRG Oncology Operations offices, SDMCs, and Biospecimen Banks today in observance of Labor Day
Reported by NRG ONCOLOGY
Presence & Recognition
NRG ONCOLOGY is hosting an interview with Dr. Ying Liu regarding the NRG-GY036 for ovarian, fallopian tube, and peritoneal cancers for the Ovarian Cancer Awareness Month.
Reported by NRG ONCOLOGY
Presence & Recognition
NRG ONCOLOGY featured ovarian cancer advocate Debbie in a participation powers research feature for WearTealDay
Reported by NRG ONCOLOGY
Presence & Recognition
NRG ONCOLOGY is hosting a webinar titled POLYP 102 Guidance on Unscheduled Colonoscopy Exams scheduled in October.
Reported by NRG ONCOLOGY
Presence & Recognition
NRG ONCOLOGY hosted the NRG ONCOLOGY Podcast on the Ovarian Awareness Month Teal Day episode featuring Dr. Ying Liu from Memorial Sloan Kettering Cancer Center discussing olapirib duration in GY036.
Reported by Stephen Chun
Presence & Recognition
NRG ONCOLOGY announced that the next session of the Protocol Support Committee's
Reported by NRG ONCOLOGY
Presence & Recognition
NRG ONCOLOGY is hosting a WearTealDay special episode comparing 1 vs 2 years of maintenance Olaparib with or without bevacizumab for patients with advanced ovarian cancer on NRG-GY036.
Reported by NRG ONCOLOGY